CD20在成年人急性B淋巴细胞白血病中的表达及其临床意义

目的 检测CD20在成年人急性B淋巴细胞白血病(B-ALL)的表达,探讨其与临床特点的相关性.方法 回顾性总结分析96例成年B-ALL患者CD20表达情况,结合其临床特性和治疗转归进行分析.结果 96例成年B-ALL患者中,CD20阳性29例(30.20%),CD20阴性67例(69.79%).CD20阳性组与阴性组男女比分别为1.42∶1和1.79∶1(x2=0.27,P＞0.05),中位年龄分别为28岁与23岁,肝脾及淋巴结浸润比例分别为44.83%和41.38%、40.30%和35.82%,髓系抗原表达比例分别为51.72%与56.72%,Ph染色体和bcr-abl融合基因阳性比例分别为24.14%与28.36%,4周内完全缓解率分别为73.08%与68.85%,差异均无统计学意义(P值均＞0.05).在复发率和3年总体生存率上,CD20阳性组分别为54.55%与14.80%,CD20阴性组分别为29.63%与37.30%,两组间差异有统计学意义(x2=0.42,x2=5.31;P值均＜0.05).结论 CD20在成年人B-ALL表达与临床特点无相关性,但对判断患者的预后有一定的指导意义.

Expression of CD20 in adult B-lineage acute lymphoblastic leukemia and its clinical significance

Objective To explore the clinical significance of expression of the CD20 in 96 adults B-lineage acute lyrnphoblastic leukemia (B-ALL). Methods The CD20 expression of 96 acute lymphoblastic leukemia patients were determined by flow cytometry. The characteristics ,examination results and outcome were analyzed retrospectively. Results Out of the 96 patients, there were 29 (30.20 %) patients with CD20positive and 67 (69.79 %) patients with CD20 negative. The distribution of age, infiltration of liver, spleen, and lymphnodes, the expression of myeloid lineage marker, the incidence of Ph chromosome and bcr-abl fusion gene and the complete remission rate within 4 weeks between CD20 positive and negative groups showed no significant differences (P ＞ 0.05). The relapse rate and 3 year over survival rate of adults B-ALL in CD20 positive and negative groups were 54.55 % and 14.80 %, 29.63 % and 37.30 % respectively with a significant differences (x2 = 0.42, 5.31, P＜ 0.05). Conclusion The expression of CD20 in adult B-ALL appears to be not associated with clinical features and CD20 expression in adult B-ALL cells appears to be associated with poor prognosis.